Slide 1: Investor Relations 3QFY08 Conference Call
Exhibit 99.1 Investor Relations 3QFY08 Conference Call July 15, 2008
Slide 2: Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 With the exception of historical information, the matters discussed in this presentation are forward looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ si
Slide 3: Introduction and Welcome
Introduction and Welcome • Introduction and Welcome • Agenda – Third Fiscal Quarter FY 2008 summary – Strategy Going Forward – Questions and Answers
Slide 4: Third Fiscal Quarter 2008 Summary
Third Fiscal Quarter 2008 Summary • Gross revenues = $2.97 MM (increase of 12.8% from 3Q07) – Pharmaceutical software and services = $1.97 MM (up 19.0% from 3Q07) • Record high quarter – Words+ subsidiary = $993,000 (up 2.2% from 3Q07) • Record high quarter • Shipments of Say it! SAM products going
Slide 5: Nine Months 2008 Summary
Nine Months 2008 Summary • Gross revenues = $7.13 MM (increase of 7.7% from 3Q07) – Pharmaceutical software and services = $4.96 MM (up 15.7% from 3Q07) • GastroPlus and ADMET Predictor are the major contributors to the increase. – Words+ subsidiary = $2.17 MM (down 6.9% from 3Q07) • Say-it! SAM PDA
Slide 6: Income Tax Discussion
Income Tax Discussion • After the tax issues we had last year, we hired two different tax expert companies to analyze our taxes: – A company to work on our deferred tax analysis every quarterly report and to prepare our income tax returns – A tax credit specialist company to find potential unused ta
Slide 7: Guidance
Guidance • Revenue guidance provided during last quarter’s conference call was for an additional $1 million in consolidated revenues • As of the end of the 3rd quarter, we are $510,000 ahead of last year • Although we are working hard to achieve the additional $490,000 we would need in the 4th quart
Slide 8: Progress
Progress • ADMET Predictor/ADMET Modeler – Version 3.0 released in June • More than 50 new quantum charge-related descriptors added from the work we did under our Phase I SBIR project last year, and subsequent work funded internally • All existing property models retrained with the new descriptors,
Slide 9: Progress - ClassPharmer and DDDPlus
Progress - - 2 • ClassPharmer – Version 4.5 released in June – Pair SAR (structure-activity relationship) feature allows rapid detection of small changes in molecular structure that result in large changes in properties – Full integration with ADMET Predictor provides powerful new molecule design to
Slide 10: Progress - GastroPlus
Progress - - 3 • GastroPlus – Version 6.0 released in June • Additional improvements to our new IVIVCPlus™ Module - important capability for generic and innovator companies • PKPlus™ Module - pharmacokinetics for oral and iv doses • PDPlus™ Module - pharmacodynamic (response) modeling – Pfizer poste
Slide 11: Progress - Words+ subsidiary
Progress - - 4 • Words+ subsidiary – Third quarter set new record for revenues. We expect Words+ to continue to make a positive contribution going forward – New Say-it! SAM PDA-based communication system is selling very well - shipments this fiscal year are more than 80% ahead of last year – Major n
Slide 12: Strategy Going Forward
Strategy Going Forward • Expand product line and services, marketing and sales efforts – Pharmaceutical software and services • Hiring new scientists to expand Life Sciences team • Continue to enhance current products • Develop new products and services • Continue to seek accretive acquisitions with
Slide 13: Summary
Summary • Company is financially very strong with steadily growing cash position and no debt • Growing, dedicated and extremely talented workforce • Marketing and sales efforts are being expanded in both businesses • Acquisitions are a major part of our growth strategy and we continue to be on the h
Slide 14: Questions?
Questions? simulationsplus, inc, Of
Slide 15: Slide 15